Valuation: Ascletis Pharma Inc.

Capitalization 1.1TCr 1.23TCr 157.72Cr 135.06Cr 125.6Cr 117.09Cr 218.79Cr 14TCr 234.67Cr 1.45TCr 568.72Cr 6.8TCr 591.48Cr 579.35Cr 25TCr P/E ratio 2025 *
-30.9x
P/E ratio 2026 * -59.9x
Enterprise value 902.52Cr 1.01TCr 129.43Cr 110.83Cr 103.07Cr 96Cr 179.55Cr 12TCr 192.58Cr 1.19TCr 466.71Cr 5.58TCr 485.38Cr 475.43Cr 20TCr EV / Sales 2025 *
11,058x
EV / Sales 2026 * 31.7x
Free-Float
25.77%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.29%
1 week+4.38%
Current month+12.99%
1 month-11.36%
3 months+30.40%
6 months+45.42%
Current year+12.99%
More quotes
1 week 11.88
Extreme 11.88
13.16
1 month 11.08
Extreme 11.08
14.33
Current year 11.3
Extreme 11.3
13.16
1 year 2.84
Extreme 2.84
18.75
3 years 0.76
Extreme 0.76
18.75
5 years 0.76
Extreme 0.76
18.75
10 years 0.76
Extreme 0.76
18.75
More quotes
Manager TitleAgeSince
Chief Executive Officer 63 -
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 07/10/2019
Director TitleAgeSince
Chairman 63 -
Director/Board Member 53 01/04/2018
Director/Board Member 52 13/03/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+3.29%+4.38%+304.72%+189.21% 157.72Cr
-3.58%+0.62%+10.21%+7.48% 7.88TCr
-0.37%+87.80%+87.80%+87.80% 5.87TCr
+0.67%+7.96%+32.60%+225.21% 5.59TCr
-1.02%+2.99%-38.10%-38.75% 5.67TCr
-1.06%+6.30%+24.73%-35.56% 2.72TCr
-0.51%+4.46%+50.74%+32.17% 2.09TCr
-0.11%+6.88%+163.96%+125.06% 1.97TCr
+6.79%+11.82%+65.11%+1,364.18% 1.73TCr
-0.53%+4.66%+164.24%+781.19% 1.48TCr
Average +0.70%+5.16%+86.60%+273.80% 3.52TCr
Weighted average by Cap. +0.07%+4.94%+41.59%+153.03%
See all sector performances

Financials

2025 *2026 *
Net sales 8L 9L 1L 1L 93.21T 86.9T 2L 1.05Cr 2L 10.74L 4L 50.47L 4L 4L 1.85Cr 26Cr 29Cr 3.71Cr 3.18Cr 2.96Cr 2.76Cr 5.15Cr 334.51Cr 5.52Cr 34Cr 13Cr 160.03Cr 14Cr 14Cr 586.76Cr
Net income -37Cr -41Cr -5.29Cr -4.53Cr -4.21Cr -3.93Cr -7.34Cr -476.94Cr -7.87Cr -49Cr -19Cr -228.17Cr -20Cr -19Cr -836.6Cr -14Cr -15Cr -1.97Cr -1.69Cr -1.57Cr -1.46Cr -2.73Cr -177.57Cr -2.93Cr -18Cr -7.1Cr -85Cr -7.39Cr -7.24Cr -311.48Cr
Net Debt -197.28Cr -220.57Cr -28Cr -24Cr -23Cr -21Cr -39Cr -2.55TCr -42Cr -259.52Cr -102.01Cr -1.22TCr -106.1Cr -103.92Cr -4.47TCr -279.57Cr -312.58Cr -40Cr -34Cr -32Cr -30Cr -56Cr -3.61TCr -60Cr -367.79Cr -144.57Cr -1.73TCr -150.36Cr -147.27Cr -6.34TCr
More financial data * Estimated data
Logo Ascletis Pharma Inc.
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
Employees
208
More about the company
Date Price Change Volume
13/26/13 12.87 $ +3.29% 24,62,000
12/26/12 12.46 $ -1.03% 15,24,000
09/26/09 12.59 $ +0.56% 14,79,700
08/26/08 12.52 $ +1.05% 28,44,000
07/26/07 12.39 $ +3.25% 23,58,736

Delayed Quote Hong Kong S.E., January 13, 2026 at 01:38 pm IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.14CNY
Average target price
19.09CNY
Spread / Average Target
+71.33%
Consensus

Quarterly revenue - Rate of surprise